RxDoctor Payments Data

Shimul Shah, MD

Transplant Surgery · Boston, MANPI 1811962327

Payments from drug & device makers

What this record shows

The money is spread across several categories — consulting fees (37.9%), speaking fees and education — rather than concentrated in one kind of arrangement. 9 manufacturers reported payments, led by Genentech USA, Inc. at 39.3% of the total. Reporting peaked in 2023 at $3,885 and has fallen 99.5% since, to $20 in 2025.

$8,347in general payments, 2019–2025

Across 22 payments — averaging $379.40 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Genentech USA, Inc.$3K
  • Intuitive Surgical$2K
  • Sirtex Medical Inc$2K
  • Organ Recovery Systems, Inc.$920
  • Medtronic$154
  • Johnson & Johnson$39
  • plus $56 from 3 others
$1,895,433in research payments, 2019–2025

Across 20 payments — averaging $94,772 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Organ Recovery Systems, Inc.$1.9M

What the payments were for

  • Consulting fees$3,16538%
  • Speaking & faculty fees$1,75021%
  • Travel & lodging$6067%
  • Food & beverage$1,32616%
  • Education$1,50018%

General payments by program year

19
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$8,347 in reported general payments places this provider in the 85th percentile of 23 transplant surgery providers in Massachusetts.

See all transplant surgery providers in Massachusetts

Medicare billing

Part B allowed, 2024
$88,975
Medicare patients
74
Services billed
370

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Valganciclovir Hcl14$2,555
Prednisone14$80
Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim12$65

Paid to pharmacies, not to this prescriber.

Other transplant surgery in Boston

See the full list for Massachusetts

Where these figures come from

Is this you, or does something look wrong? →